- Ixion Names Heimer VP Product Development
-
 ALACHUA, FL. February 6, 2001 - Jon Heimer has joined Ixion, a clinical stage biotech company focused on cell-based treatments of metabolic disorders, as vice president of product development.
- Heimer will play a key role in Ixion's future. He is the most senior executive responsible for the design and development of Ixion's product line including its initial manufacturing efforts. He will also oversee the development of the product line through the design phase up to the release to production, and will oversee product/project teams from conception through the development cycle.
- Before joining Ixion, Heimer was Business Development Manager of CellFactory, a stem cell company in Uppsala, Sweden and a consultant to Q-Med, AB. Previously from 1998 to 2001, he held various positions, ultimately business unit manager software with PharmaSoft. From 1994 to 1997, Mr. Heimer was the Global Marketing Manager and R&D Project Manager, Q-Med. AB. Mr. Heimer has a master of business administration from IHM Business School, a diploma in marketing from the Swedish Association of Marketing, a degree in business administration from Uppsala University, and an engineering degree from the College of Engineering, Uppsala, Fyrisskolan.
- Alachua, Fla.-based Ixion is the world's leader in developing diagnostic and prevention options for oxalate-related disorders, such as kidney stones, primary hyperoxaluria, Crohn's Disease, and cystic fibrosis. Ixion also is developing cell therapy products to treat diabetes.
- "We are very pleased to have Jon Heimer join us from our parent company, Q-Med. His experience in product development, project management, and quality systems will significantly strengthen the depth and expertise of our management team as the Company faces the important new challenges of moving our initial products from research, through clinical trials, and into the marketplace. We are especially happy that he will be here as we commence our initial clinical trial for IxOC-2, our oxalate control product, scheduled for early spring," said Weaver Gaines, Ixion chairman and CEO.
- For more information about Ixion, visit www.ixion-biotech.com or call 386-418-1428.
- This news release includes forward-looking statements involving risks and uncertainties, such as risks associated with pre-clinical and clinical development in the biotechnology industry, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments and costs of developing, producing and selling products.
- Contacts:
-
-
-
-
-
-
-
-
- Weaver H. Gaines
Ixion Biotechnology, Inc.
386-418-1428 (voice)
386-418-1583 (fax)
Info@ixion-biotech.com
Lisette Hilton
561-392-5649 (voice)
561-392-7496 (fax)
Info@ixion-biotech.com
-
-
-
|
